Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis

Moro, Francesca; Simone, Clara De; Morciano, Andrea; Tropea, Anna; Sagnella, Francesca; Palla, Carola; Scarinci, Elisa; Teti, Angela; Caldarola, Giacomo; D’agostino, M. A.; Mancuso, Stefano; Lanzone, Antonio; Apa, Rosanna

doi:10.1016/j.fertnstert.2012.10.040

Cited by 26 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fatty liver disease often provides an indication of potential underlying diseases, including cardiovascular disease, MetS, diabetes, obstructive sleep apnoea and obesity. Other less‐common associations are fatty pancreas, hypothyroidism, colon polyps, elevated uric acid levels, vitamin D deficiency and polycystic ovaries …”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

Prussick

Miele

2018

Br J Dermatol

View full text Add to dashboard Cite

Summary Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low‐grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor‐α and interleukin‐6) and hepatokines, and decreased levels of adiponectin, an anti‐inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

Prussick

Miele

2018

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…Health care providers should be aware of the possible coexistence of polycystic ovary syndrome and consider directed testing if suggestive symptoms or signs are present (eg, oligomenorrhea, hirsutism). 38 …”

Section: Methodsmentioning

confidence: 99%

Pediatric Psoriasis Comorbidity Screening Guidelines

et al. 2017

View full text Add to dashboard Cite

IMPORTANCE-Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE-To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW-A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence.FINDINGS-Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs Osier et al.

show abstract

“…Indeed, pregnant psoriatic women are more likely to be overweight, smoke, have a diagnosis of depression and delay taking vitamins than non‐psoriatic women, and these factors are all associated with an adverse pregnancy outcome. Another explanation for this association, in particular in psoriatic women, may be the high prevalence of polycystic ovary syndrome (PCOS) [Moro et al., ]. In fact, recently we conducted a study that showed that the prevalence of PCOS in the psoriatic cohort ( n = 51) was remarkably greater (about 47%) than that seen in non‐psoriatic women ( n = 102) matched for age and body mass index; this was independent of some potential confounders, such as metabolic syndrome, hypertension and family history of early coronary disease.…”

Section: Introductionmentioning

confidence: 99%

A Possible Role of Polycystic Ovary Syndrome for Pregnancy Complications in Women with Psoriasis

Simone

Caldarola

Corbeddu

et al. 2014

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Psoriasis is a common, chronic, relapsing immune-mediated inflammatory disease (IMID) of the skin. IMIDs are multifactorial diseases characterized by common molecular pathways leading to a systemic inflammation. Patients with an IMID are also at higher risk of developing co-morbidities, such as adverse pregnancy outcomes, than the general population. A higher rate of pregnancy complications have been seen in inflammatory bowel disease and rheumatoid arthritis. The data for psoriasis are inconsistent but it appears that women with moderate-to-severe psoriasis may also have an increased risk of poor pregnancy outcomes. The cause of this association is unknown, although it may be related to elevated proinflammatory cytokines such as IL-6 and TNF-α, the high prevalence of comorbidities and other unhealthy behaviours, or the high prevalence of polycystic ovary syndrome (PCOS). In a recent study, PCOS prevalence in a psoriatic cohort (n = 51) was higher than in non-psoriatic women (n = 102) (47% versus 11%), and women with PCOS and psoriasis had a greater probability of insulin resistance, hyperinsulinaemia, and dyslipidaemia as well as a more severe skin condition, than those with psoriasis alone. Further studies are necessary to clarify the impact of psoriasis on pregnancy and in particular if these effects are mediated by concomitant PCOS.

show abstract

Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis

Cited by 26 publications

References 35 publications

Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

Pediatric Psoriasis Comorbidity Screening Guidelines

A Possible Role of Polycystic Ovary Syndrome for Pregnancy Complications in Women with Psoriasis

Contact Info

Product

Resources

About